Co-Diagnostics (CODX) ‘Neutral’ Rating Confirmed at HC Wainwright

HC Wainwright maintained its neutral rating on the stock Co-Diagnosis (NASDAQ:CODX – Free Report) in a report published on Monday morning, Benzinga reports. The current target price for the company’s stock is $2.00.

Co-Diagnostics turnover decreased by 8.8%

On Monday, the NASDAQ CODX opened at $1.45. The company’s 50-day moving average price is $1.19 and its 200-day moving average price is $1.20. The market value of the stock is $45.35 million, the PE ratio is -1.10 and the beta coefficient is -0.85. Co-Diagnostics has a 12 month low of $0.98 and a 12 month high of $1.89.

Co-Diagnostics (NASDAQ:CODX – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). Co-Diagnostics achieved a negative return on equity of 42.35% and a negative net margin of 582.36%. The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $3.10 million. In the same quarter last year, the company posted earnings per share ($0.20). As a group, sell-side analysts forecast that Co-Diagnostics will post earnings per share of -1.33 for the current year.

Institutional inflows and outflows

The hedge fund recently increased its holdings in Co-Diagnostics stock. Kestra Advisory Services LLC has increased its position in Co-Diagnostics, Inc., according to its latest 13F filing with the SEC. (NASDAQ:CODX – Free Report) up 108.8% in the third quarter. The institutional investor owned 128,560 shares of the company’s stock after purchasing an additional 66,989 shares during the period. At the end of the last quarter, Kestra Advisory Services LLC held 0.42% of Co-Diagnostics worth $136,000. Institutional investors and hedge funds own 14.99% of the company’s shares.

Co-diagnosis company profile

(Get the free report)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures and markets diagnostic test reagents that function by detecting and/or analyzing nucleic acid molecules in the United States and around the world. The company offers the Co-Dx PCR platform, a polymerase chain reaction (PCR) test for patients in point-of-care and home-based settings.

Featured Stories

Receive co-diagnosis news and assessments daily – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Co-Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.